XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
General (Detail Textuals)
 1 Months Ended 3 Months Ended 11 Months Ended
Mar. 16, 2021
USD ($)
shares
Mar. 15, 2021
USD ($)
$ / shares
Apr. 25, 2022
USD ($)
Apr. 30, 2021
USD ($)
Mar. 31, 2022
USD ($)
$ / shares
Mar. 31, 2021
USD ($)
Mar. 31, 2022
USD ($)
$ / shares
shares
Restructuring Cost and Reserve [Line Items]              
Number of common shares for each preferred share converted | shares 1            
Reverse stock split conversion ratio 0.04            
Market capitalization amount $ 58,700,000            
Share-based compensation expense         $ 874,000 $ 43,000  
Isuuance and sale value of ADSs and warrants   $ 45,500,000          
Warrant exercise price | $ / shares   $ 17.35          
Warrants exercisable period   5 years          
Proceeds from exercise of warrants   $ 4,500,000          
Amount of total sale and transfer of compounds and products kestrel paid   $ 1,000,000.0          
American Depository Shares ADSs [Member] | At the Market Offering Agreement with Cantor Fitzgerald & Co. [Member]              
Restructuring Cost and Reserve [Line Items]              
Aggregate offering price       $ 75,000,000      
Shares issued under agreement | shares             699,806
Average price of shares issued under agreement | $ / shares         $ 22.75   $ 22.75
Gross proceeds from sale under agreement             $ 15,900,000
American Depository Shares ADSs [Member] | At the Market Offering Agreement with Cantor Fitzgerald & Co. [Member] | Subsequent Event [Member]              
Restructuring Cost and Reserve [Line Items]              
Gross proceeds from sale under agreement     $ 18,125,000        
Former Chemomab Security Holders [Member]              
Restructuring Cost and Reserve [Line Items]              
Shareholding percentage immediately following the merger 90.00%            
Number of common shares for each preferred share converted | shares 65,675,904            
Accumulated deficit $ 2,500,000            
Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]              
Restructuring Cost and Reserve [Line Items]              
Number of ordinary shares represented by each ADS (in shares) | shares 20            
Number of ADS issued and outstanding after the merger | shares 12.86            
Number of shares diluted after the merger | shares 8,078,727            
Number of shares after merger for each share of Chemomab | shares 9,003,357